An open-label, parallel, single ascending dose (SAD) study investigating the pharmacokinetics, dose proportionality, and safety of K102 in patients with Parkinson's disease (PD)
Latest Information Update: 24 Aug 2020
At a glance
- Drugs K 102 (Primary)
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Kashiv BioSciences
Most Recent Events
- 19 May 2020 Status changed from recruiting to active, no longer recruiting.
- 30 Jan 2020 New trial record